Press Releases

« Back to news

LogicBio Therapeutics to Participate in Upcoming Investor Conferences

June 1, 2021 at 4:05 PM EDT

LEXINGTON, Mass., June 1, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced that Frederic Chereau, chief executive officer of LogicBio, will participate in virtual fireside chats at the following upcoming investor conferences:

  • Jefferies Virtual Healthcare Conference, Friday, June 4, at 9:30 AM ET.
  • JMP Securities Life Sciences Conference, Wednesday, June 16, at 2:00 PM ET.

Where applicable, live webcasts of the fireside chats can be accessed through the Investors section of the Company's website at https://investor.logicbio.com.

About LogicBio Therapeutics 

LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood. The Company's proprietary GeneRide™ platform is a new approach to precise gene insertion that has the potential to harness a cell's natural DNA repair process leading to durable therapeutic protein expression levels. LogicBio's cutting-edge sAAVy™ capsid development platform is designed to support development of treatments in a broad range of indications and tissues. The Company is based in Lexington, MA. For more information, visit https://www.logicbio.com/, which does not form a part of this release.

Media Contacts:
Adam Daley
Berry & Company Public Relations
W: 212-253-8881
C: 614-580-2048
adaley@berrypr.com

Jenna Urban
Berry & Company Public Relations
W: 212-253-8881
C: 203-218-9180
jurban@berrypr.com 

Investor Contacts:
Matt Lane
Gilmartin Group
(617) 901-7698
matt@gilmartinir.com

Cision View original content:http://www.prnewswire.com/news-releases/logicbio-therapeutics-to-participate-in-upcoming-investor-conferences-301303288.html

SOURCE LogicBio Therapeutics, Inc.